Key facts
- It has raised $45.1M; the latest was Later Stage VC ($40.6M) in Aug 2025.
- Notable investors include YuanBio Venture Capital, Chuchang Investment Group, China Financial Innovation Investment, Hubei High-tech Industry Investment Group, Luojia Capital — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Kanglu Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Kanglu Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kanglu Bio
Developer and provider of fluorescence in situ hybridization (FISH) probe technology for precise medical diagnosis. The company specializes in developing advanced medical diagnosis products including hybridization probes, human geno-typing testing kits, and automatic FISH pretreatment systems, aiming to provide multi-disciplinary diagnostic products for major diseases such as cancer, cardiovascular and cerebrovascular diseases.
- Sector
- Healthcare
- HQ
- Wuhan, China
- Founded
- 2013
- Website
- healthcare-bio.com/
- Ownership
- Privately Held (backing)
Kanglu Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kanglu Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kanglu Bio in its N-PORT filings yet. We sweep new filings monthly.